Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Bladder Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT01331824
What this trial is testing

Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma

Who this might be right for
Bladder Cancer
Matthew Galsky 22
Testing effectiveness (Phase 2)Study completedNCT02109328
What this trial is testing

Alisertib in Chemotherapy-pretreated Urothelial Cancer

Who this might be right for
Bladder CancerTransitional Cell Carcinoma
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 22
Early research (Phase 1)Study completedNCT00082823
What this trial is testing

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Who this might be right for
Cancer
Regeneron Pharmaceuticals 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT02202772
What this trial is testing

Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

Who this might be right for
Urothelial Carcinoma of the Urinary Bladder
Guarionex J. Decastro 51
Not applicableEnded earlyNCT05052372
What this trial is testing

Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Who this might be right for
Bladder CancerUrothelial CarcinomaTransitional Cell Carcinoma+10 more
xCures 2
Early research (Phase 1)UnknownNCT03634982
What this trial is testing

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

Who this might be right for
Solid Tumors
Revolution Medicines, Inc. 133
Large-scale testing (Phase 3)Study completedNCT02773849
What this trial is testing

ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

Who this might be right for
Superficial Bladder Cancer
Ferring Pharmaceuticals 157
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07189793
What this trial is testing

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

Who this might be right for
Urinary Bladder NeoplasmsCarcinoma, Transitional CellCarcinoma in Situ of Bladder+1 more
First Affiliated Hospital of Wenzhou Medical University 106
Large-scale testing (Phase 3)Looking for participantsNCT06545955
What this trial is testing

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Who this might be right for
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Ferring Pharmaceuticals 250
Early research (Phase 1)Study completedNCT00020579
What this trial is testing

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 75
Large-scale testing (Phase 3)Active Not RecruitingNCT04452591
What this trial is testing

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Who this might be right for
Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
CG Oncology, Inc. 190
Testing effectiveness (Phase 2)WithdrawnNCT01700010
What this trial is testing

Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer

Who this might be right for
Urothelial CancerBladder Cancer
University of Michigan Rogel Cancer Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT04640623
What this trial is testing

TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

Who this might be right for
Urinary Bladder Neoplasms
Janssen Research & Development, LLC 220
Testing effectiveness (Phase 2)WithdrawnNCT03999658
What this trial is testing

STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Who this might be right for
Peripheral T Cell LymphomaDiffuse Large B Cell LymphomaBiliary Tract Cancer+1 more
Sorrento Therapeutics, Inc.
Large-scale testing (Phase 3)Active Not RecruitingNCT05024773
What this trial is testing

Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Who this might be right for
Bladder Carcinoma in Situ (CIS)
Fidia Farmaceutici s.p.a. 130
Large-scale testing (Phase 3)Active Not RecruitingNCT04579224
What this trial is testing

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Who this might be right for
Metastatic Bladder Urothelial CarcinomaMetastatic Urothelial CarcinomaRefractory Bladder Urothelial Carcinoma+2 more
National Cancer Institute (NCI) 184
Early research (Phase 1)Looking for participantsNCT06916494
What this trial is testing

Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer

Who this might be right for
Muscle Invasive Bladder Cancer
First Affiliated Hospital of Chongqing Medical University 10
Testing effectiveness (Phase 2)Looking for participantsNCT04752722
What this trial is testing

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Who this might be right for
Superficial Bladder CancerNon-muscle Invasive Bladder Cancer With Carcinoma in SituNon-muscle Invasive Bladder Cancer
enGene, Inc. 350
Testing effectiveness (Phase 2)Study completedNCT02581982
What this trial is testing

Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer

Who this might be right for
Transitional Cell Carcinoma
Wake Forest University Health Sciences 27
Early research (Phase 1)Study completedNCT03985072
What this trial is testing

Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor

Who this might be right for
Tumor, SolidGall Bladder CancerCervical Cancer+3 more
Andes Biotechnologies 67
Next Page